Medicine Description glyxambi 25/5 mg
glyxambi 25/5 mg tablets is a medication that combines two active ingredients: empagliflozin and linagliptin. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by preventing the reabsorption of glucose in the kidneys, which leads to increased glucose excretion through urine. This mechanism helps lower blood glucose levels in individuals with type 2 diabetes. Linagliptin, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's own incretin hormones, which help to regulate blood sugar levels. By inhibiting the DPP-4 enzyme, linagliptin increases the levels of active incretins that stimulate insulin release and decrease glucagon secretion, particularly after meals. The combination of these two mechanisms provides a dual approach to managing blood glucose levels effectively, offering improved glycemic control in patients with type 2 diabetes.
Indications and Uses of glyxambi 25/5 mg tablets
- Management of blood glucose levels in adults with type 2 diabetes mellitus.
- As an adjunct to diet and exercise in patients who have not achieved adequate glycemic control with other medications.
- Used in combination with other antidiabetic agents when additional glycemic control is needed.
Side Effects of glyxambi 25/5 mg tablets
- Hypoglycemia, particularly when used with other antidiabetic medications.
- Gastrointestinal issues such as nausea, vomiting, and diarrhea.
- Urinary tract infections due to increased glucose in the urine.
- Possible allergic reactions, including rash or itching.
- Risk of dehydration and hypotension.
Storage and Handling
Store glyxambi 25/5 mg tablets at room temperature, away from moisture and heat. Ensure the medication is kept in its original packaging to protect it from light. Keep out of reach of children.
Patient Advice and Precautions
Patients should be counseled on the importance of adhering to their prescribed diet and exercise regimen while taking glyxambi. Regular monitoring of blood sugar levels is essential to ensure effective management. Patients should be informed about signs of hypoglycemia and should carry a source of fast-acting sugar. It is important to stay hydrated and report any symptoms of dehydration, such as excessive thirst or dry mouth. Discuss any new medications or supplements with a healthcare provider to avoid potential interactions.